Ardelyx (ARDX) vs Oric Pharmaceuticals (ORIC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Oric Pharmaceuticals (ORIC) has outperformed Ardelyx (ARDX) over the past year, losing 36.7% versus a loss of 44.8%. Over five years, ARDX leads with a +234.8% price change compared with -48.6% for ORIC. Oric Pharmaceuticals is the larger company by market cap ($764.9 million vs $751.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARDX | ORIC |
|---|---|---|
| Share price | $2.99 | $7.36 |
| Market cap | $751.60M | $764.94M |
| 1-day change | -2.29% | -4.42% |
| YTD return | -48.71% | -10.02% |
| 1-year return | -44.83% | -36.66% |
| 5-year return | +234.83% | -48.64% |
| Forward P/E | 18.92 | — |
| EPS (TTM) | $-0.23 | $-1.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $407.32M | — |
| Revenue growth (YoY) | +22.09% | — |
| Net income (latest FY) | $-61.60M | $-129.47M |
| Gross margin | 90.29% | — |
| Operating margin | -10.06% | — |
| Net margin | -15.12% | — |
| 52-week high | $8.40 | $14.68 |
| 52-week low | $2.80 | $7.23 |
| Distance from 52-week high | -64.40% | -49.86% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +318.06% | +194.97% |
| Average volume | 4.46M | 1.59M |
| Shares outstanding | 251.37M | 103.93M |
| Employees | 489 | 111 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Ardelyx
ARDX stock →Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 489 employees
About Oric Pharmaceuticals
ORIC stock →ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study.
Health Care · Biotechnology: Pharmaceutical Preparations · 111 employees
ARDX vs ORIC FAQ
Which is bigger, Ardelyx or Oric Pharmaceuticals?
Oric Pharmaceuticals (ORIC) is larger, with a market capitalization of $764.94M compared with $751.60M for Ardelyx (ARDX).
Which stock has performed better over the past year, ARDX or ORIC?
ORIC returned -36.66% over the past 12 months, compared with -44.83% for ARDX (price return, excluding dividends). Past performance does not predict future results.
Are Ardelyx and Oric Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.